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Abstract
The genes and cells that mediate genetic associations identiﬁed through genome-wide association studies (GWAS) are only
partially understood. Several studies that have investigated the genetic regulation of gene expression have shown that disease-
associated variants are over-represented amongst expression quantitative trait loci (eQTL) variants. Evidence for colocalisation of
eQTL and disease causal variants can suggest causal genes and cells for these genetic associations. Here, we used colocalisation
analysis to investigate whether 595 genetic associations to ten immune-mediated diseases are consistent with a causal variant
that regulates, in cis, gene expression in resting B cells, and in resting and stimulatedmonocytes. Previously published candidate
causal genes were over-represented amongst genes exhibiting colocalisation (odds ratio > 1.5), and we identiﬁed evidence for
colocalisation (posterior odds > 5) between cis eQTLs in at least one cell type and at least one disease for six genes:ADAM15, RGS1,
CARD9, LTBR, CTSH and SYNGR1. We identiﬁed cell-speciﬁc effects, such as for CTSH, the expression of which in monocytes, but
not in B cells, may mediate type 1 diabetes and narcolepsy associations in the chromosome 15q25.1 region. Our results
demonstrate the utility of integrating genetic studies of disease and gene expression for highlighting causal genes and cell types.
Introduction
Genome-wide association studies (GWAS) have successfully
identiﬁed many regions associated with a variety of diseases
and other traits. However, the genes and cells that mediate
these genetic associations remain only partially understood. En-
richment of disease-associated single-nucleotide polymorph-
isms (SNPs) amongst expression quantitative trait loci (eQTL)
SNPs (1) indicates that a proportion of disease associations may
bemediated through gene regulation. In the casewhere a disease
association ismediated through its effect on gene expression, we
would expect the eQTL and disease signal to occur at the same
causal variant. However, as causal variants cannot be identiﬁed
from genetic association data alone, showing that a single SNP
is associated with both traits is not sufﬁcient to conﬁrm
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colocalisation, because the same situation could arise if two dis-
tinct causal variants were in linkage disequilibrium (LD) (2). We
have previously used proportional colocalisation testing to
show that cis eQTLs in resting monocytes are consistent with a
shared causal variant for type 1 diabetes (T1D) in 21 genes across
14 T1D-associated regions (3). However, this analysis was limited
by an inability to distinguish lack of statistical power from true
colocalisation because the tested null hypothesis of colocalisa-
tion also corresponds to no association.
More recently, a Bayesian colocalisationmethod has been de-
veloped that assesses the support for multiple hypotheses and
can distinguish lack of association from colocalisation or distinct
associations (4). The Bayesian approach summarises evidence in
a genetic region for ﬁve mutually exclusive hypotheses
simultaneously:
H0: there exist no causal variants for either trait;
H1: there exists a causal variant for one trait only, disease;
H2: there exists a causal variant for one trait only, gene
expression;
H3: there exist two distinct causal variants, one for each trait;
H4: there exists a single causal variant common to both traits.
Support for each is quantiﬁed in terms of posterior probabilities,
denoted by PP0, PP1, PP2, PP3 or PP4, corresponding to the ﬁve hy-
potheses. In other words, posterior probabilities can be used to
measure how likely each of the hypotheses are, given our prior
beliefs of association and colocalisation, and the data on genetic
association to disease and gene expression.
Here, we present the ﬁrst application of Bayesian colocalisa-
tion analysis to integrate disease GWAS and eQTL data in order
to highlight candidate causal genes and cells for ten immune-
mediated diseases: autoimmune thyroid disease—ATD (5), celiac
disease—CEL (6), Crohn’s disease—CRO (7), multiple sclerosis—
MS (8), narcolepsy—NAR (9), primary biliary cirrhosis—PBC (10),
psoriasis—PSO (11), rheumatoid arthritis—RA (12), T1D (13) and
ulcerative colitis—UC (7). Given the reported cell and state speci-
ﬁcity of some eQTLs (14–16), it is important to consider eQTLs
from primary immune cells, both resting and stimulated, and
we used gene expression data from puriﬁed primary monocytes,
both stimulated and resting (17,18), and resting B cells (19).
Results
We considered a total of 595 published disease susceptibility re-
gions for the ten immune-mediated diseases with summary as-
sociation data available through http://www.immunobase.org
(Table 1). Given the shared aetiology of many of these diseases,
this corresponded to 154 non-overlapping regions. For each dis-
ease, dense genotype coverage is available through the Immuno-
Chip (20), a custom SNPmicroarray that provides common dense
variant (SNP and small indels) coverage for regions associated
with autoimmune and inﬂammatory diseases. We used gene ex-
pression from B cells (19), monocytes (17,18) and stimulated
monocytes (interferon-γ after 24 h, IFN24; and lipopolysaccharide
after 2 h, LPS2, and 24 h, LPS24) (17) to generate cis eQTL maps of
1414 unique genes within ±200 kb of these established disease
susceptibility regions. For resting monocytes, we combined
data from two studies in a ﬁxed-effects meta-analysis. The sam-
ples in the gene expression studies had not been genotyped by
the ImmunoChip, and sowe imputed genotypes using 1000 Gen-
omes Phase 1 haplotypes to provide a dense set of genotypes, as
required by the colocalisation method. We used the Bayesian co-
localisation analysis to examine evidence for colocalisation
between disease and eQTL signals, for a total of 8369 pairwise
comparisons.
Figure 1 shows the densities of the posterior probabilities of
no association for either trait (PP0), association with exactly one
trait (PP1 + PP2) and association with both traits (PP3 + PP4). In
most cases, no evidence for association is found with either
trait and, where association is observed, it is mostly with a single
trait. Restricting attention to 1239 probe/disease pairs with PP3 +
PP4 ≥ 0.8 (suggestive of association with both traits), published
candidate causal genes are over-represented amongst pairs exhi-
biting colocalisation (odds ratio > 1, Table 2), suggesting that colo-
calising signals identify disease-relevant genes in all cells and
conditions analysed. A total of 125 genes showed eQTL signals
that overlapped with at least one disease (PP3 + PP4 ≥ 0.99,
Table 1). Of these, 28 also showed some support for colocalising
signals (PP4/PP3 > 1) but only six showed sufﬁcient support for
us to consider them ‘convincing’ (PP4/PP3 > 5, Table 3). The num-
ber of colocalising signals found reﬂects the sample numbers
available in the eQTL studies, with more pairwise colocalising
signals found in resting monocytes (n = 9) than in stimulated
monocytes (n = 6) or B cells (n = 4). A further three genes showed
weaker, but still supportive evidence (PP4/PP3 > 0.9 and PP4/PP3 > 3,
Table 3). All of these have previously been nominated as candi-
date causal genes through association of expression of disease-
associated SNPs: BLK in RA through expression in B cells (21), as
here, FAM119B as a candidate causal gene in MS through expres-
sion in whole blood (22), matching the colocalisation we observe
across B cells and monocytes, and FAM164A through expression
in lymphoblastoid cell lines (23). Supplementary Material,
Figures S1–S11 show the zoomedManhattan plots for implicated
genes and diseases in Table 3.
For each region in which at least one colocalising signal was
observed, we examined the evidence for other probes, genes
and diseases in that region (Supplementary Material, Figs S12–
S20). No colocalised signals were observed convincingly across
all cell types and conditions, emphasizing the cell- and condi-
tion-speciﬁc effects of disease causal variants. For example, colo-
calisation between reduced CTSH expression and T1D and NAR
susceptibility on chromosome 15q25.1 was seen in both resting
and stimulated monocytes but not in B cells. The monocyte
eQTL (peak SNP, rs34843303) appears to also affect expression
in B cells, but there is a stronger eQTL signal unique to B cells at
SNP rs11855406 (Supplementary Material, Fig. S5). This suggests
that disease susceptibility may be mediated through monocytes
or through another cell typewith an equivalent eQTL pattern, but
not through B cells, at least under this condition.
The design of the expression microarray occasionally in-
cludes multiple probes for a single gene in an attempt to capture
isoform-speciﬁc expression.We observed colocalisation between
PBC association marked by rs2267407 and eQTLs for SYNGR1 in
resting monocytes and B cells using the probe ILMN_1727805,
but colocalisation with only the B cell eQTL using the probe
ILMN_1810875. No convincing eQTLs were seen in stimulated
cells. ILMN_1727805 captures a single isoform whereas ILMN_
1810875 captures almost all isoforms (Fig. 2), suggesting that
there may be a monocyte-speciﬁc eQTL that does not affect ex-
pression of the long isoform captured by ILMN_1727805, and
that, therefore, perhaps only the long isoform of SYNGR1 is in-
volved in the aetiology of PBC.
Discussion
In the Bayesian colocalisation approach adopted for our analyses,
selection of prior beliefs for each hypothesis plays an important
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role. Giambartolomei et al. (4) assumed a random SNP might be
causal for either trait individually with prior probability 1 × 10−4.
We adopted the same value here as it equates to a conservative
expectation of ∼20 causal SNPs on the ImmunoChip array for
any disease and ∼1 in 20 genes having a cis eQTL in a given cell
type. Given that we are focusing on regions already known to
show genome-wide association to disease, this prior for disease
association may appear low: within any region we consider, we
do expect there to exist a causal variant. However, the samples
used to declare genome-wide association in each region are gen-
erally the same as, or a subset of, those used to generate the
summary statistics used in our analysis, and we cannot alter a
prior belief on the basis of the same datawe are about to analyse.
Giambartolomei et al. then considered prior probabilities for an
SNP being causal for both traits (p12) ranging from 1 × 10
−5 to 1 ×
10−6 and stated that consistent results were shown given those
different priors. However, for our dataset, we found results de-
pended quite substantially on the prior (Fig. 3). Whilst the inter-
pretation of the priors for association of each individual trait is
clear and we have considerable data amassed through GWAS
and eQTL studies with which to support our choice, there is sub-
stantially less data quantifying the role of eQTLs in mediating
GWAS hits to guide our choice of p12. We used a form of internal
empirical calibration (see Materials and Methods), considering a
range of values for p12 and choosing that for which the posterior
expectation of colocalisation, averaged over all regions consid-
ered, most closely resembled the prior expectation of colocalisa-
tion. We encourage other researchers to consider carefully the
parameters used to deﬁne the prior probabilities as they may
vary according to the cell type or diseases under study.
Table 1. Number of case–control subjects and disease-associated regions for pairwise colocalisation investigation
Disease Cases Controls Fairfax studies Meta-analysis Disease-eQTL.
Regions Pairs Regions Pairs Overlaps Suggestive Convincing
Autoimmune thyroid disease 2747 9364 9 125 8 65 6 2 0
Celiac disease 12 041 12 228 28 293 21 132 16 2 1
Crohn’s disease 14 763 15 977 83 1110 77 619 61 5 2
Multiple sclerosis 9772 17 376 60 883 51 484 44 11 1
Narcolepsy 1886 10 421 2 19 2 6 1 1 1
Primary biliary cirrhosis 2861 8514 17 240 13 122 18 3 2
Psoriasis 10 588 22 806 24 423 22 253 15 1 0
Rheumatoid arthritis 13 838 33 742 60 905 58 536 11 0 0
Type 1 diabetes 6693 12 420 41 625 37 320 23 6 1
Ulcerative colitis 10 920 15 977 55 787 51 422 35 4 1
At least one disease 125 28 6
Total 379 5410 340 2959
Probes within ±200 kb of the regions were included. ‘Regions’ gives the number of regions considered for each disease and ‘Pairs’ the number of probe/disease pairwise
analyses performed. Given the different chips used for expression analyses, the number of regions differed between the Fairfax (17,19) and Cardiogenics (18) studies. The
Disease-eQTL columns summarize the colocalisation analyses, giving the number of genes with a convincing eQTL overlapping a disease region (‘Overlaps’,
PP3 + PP4 > 0.99), the number of those with suggestive evidence of colocalisation with the disease signal (‘Suggestive’; PP4/PP3 > 1) and the number of those with
convincing evidence for colocalisation (‘Convincing’; PP4/PP3 > 5). The ‘Total’ row gives the total number of analyses performed (a simple sum of the numbers above).
The ‘At least one disease’ row gives the number of genes showing eQTLs that overlap with or show suggestive or convincing colocalisation with at least one disease.
Figure 1. Overall results of colocalisation analyses. No evidence for association
with either trait is found in most cases. Where association is observed, it is
mostly with a single trait. Convincing evidence for colocalisation exists in a
small proportion of genes. Shown are three posterior densities (PP0: causal
variant for neither trait—black; PP1 + PP2: causal variant for one trait—blue;
PP3 + PP4: causal variant(s) for both traits—red) of all pairwise comparisons
performed between the diseases and gene expression (unstimulated monocytes
and B cells, stimulated monocytes after 24-h IFN, 2-h LPS and 24-h LPS).
Table 2. Colocalisation is over-represented amongst probe/disease
pairs in published candidate causal genes across all ﬁve cell types
(odds ratio > 1)
Cell type In candidate
genes
Not in
candidate
genes
Odds
ratio
P
Pairs Odds Pairs Odds
Resting cells
B cells 63 0.167 94 0.106 1.575 0.514
Monocytes 92 0.195 267 0.077 2.532 0.017
Stimulated monocytes
IFN, 24 h 99 0.165 146 0.074 2.230 0.096
LPS, 2 h 46 0.179 127 0.085 2.106 0.252
LPS, 24 h 50 0.163 133 0.099 1.646 0.477
‘Pairs’ gives the number of probe/disease pairs with evidence of association with
both traits (PP3 + PP4 > 0.8) and ‘Odds’ the odds that a pairwise comparison gives
greater posterior support to a shared causal variant (PP4 > PP3). Published
candidate causal genes are as curated in ImmunoBase.
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Figure 3 also reﬂects the dependence of the prior probability of
colocalisation on the number of SNPs within a region supposed to
harbour causal variants for disease and gene expression. This is
perhaps not entirely intuitive for researchers used to thinking in
terms of single SNPs rather than regions. If a region contains Q
SNPs, then any one of them may be causal for each trait, and,
given our assumption that one SNP is causal for each trait, the
chance of the same SNP being causal for both decreases as Q
increases. Thus, ourprior probability of colocalisation is, appropri-
ately, lower in regionswhich contain a greater number of variants.
Our results do not capture all the previous candidate causal
genes that have been suggested in previous analysis of these
eQTL datasets. There are a number of reasons for this. First, be-
cause the colocalisation method requires dense genotyping, we
restricted attention to the densely genotyped target regions on
ImmunoChip, which cover ∼1% of the genome. Although en-
riched, by design, for regions harbouring autoimmune disease
variants, they do not contain associations that were published
after the design of the ImmunoChip in 2009/2010. Second, we
have been very stringent in declaring a colocalised signal. We re-
quired genome-wide signiﬁcance in the disease data, P < 10−10 in
the eQTL data, and strong evidence for colocalisation (PP4/PP3 > 5).
Whilst we provide complete results in the supplementarymater-
ial that will be useful for researchers wishing to perform further
conﬁrmatory analysis, we decided to focus in the main text only
on thosemost convincing results. Third, the colocalisationmeth-
od requires that the strongest signals in a region colocalise.
Where there are primary and secondary eQTL signals, we do
not declare colocalisation if the disease signal matches the sec-
ondary signal alone. For example, a secondary eQTL with
IL18R1 in monocytes after 2 h of LPS stimulation has been linked
with the celiac disease signal on chromosome 2q12.1 (17). Sup-
plementary Material, Figure S21 highlights the primary and sec-
ondary eQTL signals (tagged by rs4851572 and rs990171,
Table 3. Six genes showing evidence for colocalisation between gene expression and diseasewith PP3 + PP4≥ 0.99 and PP4/PP3≥ 5 and three genes
with weaker evidence (PP3 + PP4≥ 0.90 and PP4/PP3≥ 3)
Region Disease Gene Probe B cells Monocytes Mono + 24-h IFN Mono + 2-h LPS Mono + 24-h
LPS
Dir.
Assoc Coloc Assoc Coloc Assoc Coloc Assoc Coloc Assoc Coloc
PP3 + PP4≥ 0.99 and PP4/PP3≥ 5
1q22 CRO ADAM15 ILMN_1751500 0.054 0.218 0.998 22.158 0.998 22.055 0.998 22.158 0.998 22.158 †
* 1q31.2 CEL RGS1 ILMN_1656011 1.000 6.407 1.000 3.739 0.312 3.168 0.013 0.839 0.476 4.672 −
* 1q31.2 MS RGS1 LMN_1656011 1.000 5.369 1.000 3.167 0.330 2.806 0.015 0.693 0.482 4.021 −
9q34.3 CRO CARD9 ILMN_1712532 0.062 0.125 1.000 1.890 1.000 1.370 1.000 6.246 1.000 3.831 +
9q34.3 UC CARD9 ILMN_1712532 0.067 0.128 1.000 1.976 1.000 1.597 1.000 11.956 1.000 6.519 +
12p13.31 PBC LTBR ILMN_1667476 0.010 1.426 1.000 8.524 0.999 3.647 1.000 4.435 1.000 4.650 +
15q25.1 NAR CTSH ILMN_2390853 0.999 0.001 1.000 99.000 1.000 96.117 1.000 95.192 1.000 99.000 −
15q25.1 T1D CTSH ILMN_2390853 1.000 0.001 1.000 32.013 1.000 141.453 1.000 303.040 1.000 32.333 −
22q13.1 PBC SYNGR1 ILMN_1727805 1.000 13.925 1.000 11.956 0.020 0.350 0.024 0.606 0.060 0.392 ±$
22q13.1 PBC SYNGR1 ILMN_1810875 1.000 16.602 1.000 0.000 0.681 0.007 0.193 0.095 0.831 0.002 +
PP3 + PP4≥ 0.90 and PP4/PP3≥ 3
8p23.1 RA BLK ILMN_1668277 0.909 5.184 0.022 0.355 0.030 0.212 0.100 2.752 0.032 0.633 −
8q21.12 MS FAM164A ILMN_1789558 1.000 3.525 1.000 3.115 1.000 3.608 1.000 2.891 1.000 3.167 −
8q21.12 MS FAM164A ILMN_2057981 1.000 3.348 1.000 3.310 1.000 3.202 0.896 2.343 1.000 2.984 −
12q14.1 MS FAM119B ILMN_1723846 1.000 3.566 1.000 4.051 1.000 3.717 1.000 3.329 1.000 2.311 −
Assoc is the posterior probability that both the disease is associated with the region and that an eQTL exists in the indicated cell type. Coloc is the posterior odds of
colocalisation, given that both traits are associated. When data for a given probe were available from both studies of monocyte expression, we present the results
using a meta-analysis of the two. When data were only available from one study (17), we used just that study, indicated by ‘*’. Evidence of colocalising effects is
indicated by bold font, evidence of distinct effects by italic font. Allele includes risk (left) and protective alleles (right). Dir. shows whether disease risk across the
associated SNPs in a region correlates with increased (+) or decreased (−) mRNA expression of the gene. † is a secondary disease signal, and direction of effect was not
published for Crohn’s disease. $For 22q13.1/SYNGR1, the PBC risk allele correlated with increase expression in B cells (B) but decreased expression in monocytes (M).
Figure 2. In the gene SYNGR1, expression of ILMN_1810875 is captured by almost all isoforms but that of ILMN_1727805 is captured by only one isoform. Shown is gene
context plot of SYNGR1 depicting the positions of three probes.
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respectively, with the two SNPs in weak LD: r2 = 0.3) and shows
that only the secondary signal can be seen for celiac disease.
How such colocalising signals should be interpreted is not
clear. The secondary signal is likely to be relevant for both celiac
disease, and the expression of IL18R1 in LPS-stimulated mono-
cytes, but IL18R1 expression in LPS-stimulatedmonocytes cannot
itself mediate the celiac disease association in the region, other-
wise any SNP that controlled expression of IL18R1 would also
associate with celiac disease. Such results therefore, in our opin-
ion, highlight a gene but not a gene and its disease-relevant cell
and state, and it is probable that a more speciﬁc stimulation con-
dition might reveal a completely colocalised signal between
IL18R1 expression and celiac disease. A similar situation is seen
for CTSH expression in B cells and NAR and T1D susceptibility
on chromosome 15q25.1, whereas colocalisation with CTSH
expression in monocytes is clear, with both signals tagged by
SNP rs34843303 (Supplementary Material, Fig. S5).
Whilst this third reason is essentially a difference of interpret-
ation, the fourth reason that our results can differ from previous
reports is that formal colocalisation uses more information and
can therefore provide amore complete picture, than simply look-
ing for overlaps between GWAS and eQTL results. This empha-
sises the need to apply a formal colocalisation analysis. For
example, an eQTL with PDGFB in monocytes after 2 h of LPS
stimulation has been linked with PBC susceptibility on chromo-
some 22q13.1 (17). We found no evidence for colocalisation in
LPS-stimulated monocytes (PP4/PP3 = 0.1) but instead obtained
evidence for colocalisation with expression of SYNGR1 in B cells
(PP4/PP3 = 16.6). Examining the Manhattan plots (Supplementary
Material, Fig. S22) shows both the PBC signal and the SYNGR1
eQTL are tagged by rs2267407 and the PDGFB eQTL tagged by
rs968451. The two SNPs are in LD (r2 = 0.71), but the patterns of as-
sociation across the region clearly support SYNGR1 expression in
B cells rather than PDGFB expression in LPS-stimulated mono-
cytes as a disease colocalising signal. However, neither gene
has obvious functional candidacy, and the original GWAS report
highlighted MAP3K7IP1 as a candidate gene (24).
Of particular note, we did not detect strong evidence for any
colocalising signals across all studied cell types and states. For
example, we identiﬁed a disease colocalising eQTL for CARD9
and the diseases CRO and UC only in monocytes after LPS stimu-
lation, as previously reported (17). Whilst there is evidence for an
eQTL in allmonocyte states, and the odds favour colocalisation in
each, the evidence for colocalisation is strong only after LPS
stimulation. This emphasizes that disease causal variants are
likely to act in cell and/or state speciﬁcmechanisms andmotives
the collection of large, publicly available eQTL datasets for a
wider range of puriﬁed cell types and activation states that
might be more relevant to disease at the site of pathology, to en-
able researchers to more completely identify the mechanisms
underlying genetic susceptibility to disease. Despite this, when
we looked for response eQTLs (those that determine the differ-
ence between baseline and stimulated expression, rather than
those that determine expression either at baseline or stimula-
tion), we did not ﬁnd any colocalising signals. This is likely to re-
late to issues of correctly normalising expression measurements
between two samples (stimulated and unstimulated). Other colo-
calising signals were speciﬁc to individual probes, and therefore,
could indicate isoform-speciﬁc effects. This also indicates a need
to better measure expression at the isoform rather than gene
level, which is becoming possible using RNA sequencing (25).
One of the strongest colocalising signals we observe is that of
monocyte CTSH expression and T1D and NAR risk in the 15q25.1
region. CTSH is a member of the family of cathepsins and is in-
volved in apoptosis and antigen presentation, amongst other
roles. The peak CTSH eQTL SNP we ﬁnd in B cells is rs11855406,
which is in LD (r2 = 0.96) with a previously reported T1D-asso-
ciated SNP in the region, rs3825932:T>C (26). The major, T1D pre-
disposing, allele of rs3825932, T, has been shown to correlatewith
decreased CTSH mRNA and protein expression in human
B-lymphoblastoid cell lines (27), and pro-inﬂammatory cytokines
have been shown to reduce expression of CTSH in humanpancre-
atic islets where these cytokines cause stress and increased
apoptosis of islet beta cells (27).
Figure 3. Effect of prior probability p12 on the prior and posterior support for colocalisation in regions where both disease and eQTL show evidence for association
(PP3 + PP4 > 0.8). We repeated the colocalisation analysis with all prior probabilities ﬁxed as speciﬁed in Materials and Methods, except p12 which varied between 10
−7
and 10−5. For each pairwise analysis in which PP3 + PP4 > 0.8, we plotted the number of SNPs in that region against the relative posterior support for H4, deﬁned by PP4/
(PP3 + PP4) (green), and similarly the relative prior support (orange).
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Using the denser SNPmap provided by ImmunoChip, the peak
of T1D association in this region now resides at rs34843303 and
alignswith that for NAR.Wehave shownhere that the eQTL signal
in B cells is not compatiblewith T1D and NAR risk beingmediated
by CTSH expression in B cells but that in both resting and stimu-
lated monocytes is (Table 3, Supplementary Material, Fig. S5).
Autoimmune diseases are due to the inappropriate targeting by
the immune systemof host tissue, and there has beendebate, par-
ticularly with regard to T1D, as to the relative contribution of each
in the aetiology of disease. NAR is not known to involve pancreatic
islets, and the joint colocalisation of T1D andNAR association sig-
nals with CTSH expression bymonocytes suggests that the effects
of CTSH reported by Fløyel et al. (27) in islets imply that this gene
might exert its effect on T1D by variable expression in multiple
cell and tissue types.
The other strongest signal we observe linksmonocyteADAM15
expression and Crohn’s disease risk in the 1q22 region. ADAM15 is
a metalloprotease, a member of the ADAM (a disintegrin and me-
talloproteinase) protein family that includes ADAM30, an existing
candidate gene for Crohn’s disease (28). ADAM15 has been shown
to be upregulated in colon tissue from inﬂammatory bowel disease
patients comparedwithhealthy controls (29). Similarly, in ourdata,
theminor allele of rs11589479 is associated with increased disease
risk and increased expressionofADAM15. However,without know-
ing the allele-speciﬁc expression of ADAM15 in colon tissue, we
cannot determinewhether our colocalisation results reﬂect a simi-
lar eQTL proﬁle in monocytes and colon, or whether expression of
ADAM15 in tissue resident monocytes may itself increase inﬂam-
mation at the site of disease in patients with Crohn’s disease.
The relatively low rate of convincing colocalisation in our re-
sults does not indicate, in our opinion, that variation in gene ex-
pression is not a substantial mediator of genetic effects on
disease risk. Rather, it is likely to reﬂect the sample size limita-
tions of existing available eQTL studies that are focused on a sub-
set of accessible cells,mostly fromperipheral blood, andwhichare
still only of moderate sample sizes. Larger sample sizes and a
wider variety of puriﬁed cells in resting and activated states are
needed to more completely assess the role that variation in gene
expression plays in mediating genetic risk of disease. Ultimately,
speciﬁc functional studies will be required to conﬁrm or refute
the candidacyof the geneswe highlight here. Nevertheless, whilst
an estimated 50% of GWAS hits lie distal to genes (30), eQTL-dis-
ease colocalisation analyses provide a means to integrate genetic
and gene expression data to highlight directions for further study.
Materials and Methods
Case–control data
All the case–control subjects were genotyped using the Immuno-
Chip, an Illumina 200K Inﬁnium high-density array. Summary
statistics, including P-values and MAF, were downloaded from
ImmunoBase (http://www.immunobase.org, accessed 04 May
2014). The number of participants for each disease is shown in
Table 1. Samples were of European ancestry and are described
in detail in the original papers (5–13).
eQTL data
The eQTL study of monocytes (17) comprises 414 (unstimulated),
367 (IFN24), 261 (LPS2) and 322 (LPS24) volunteers of European an-
cestry recruited in the Oxfordshire area (gene expression data:
http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-2232;
genotyping data: http://www.ebi.ac.uk/ega/EGAD00010000144,
http://www.ebi.ac.uk/ega/EGAD00010000520). The eQTL study of
B cells (19) consists of 288 volunteers, of whom approximately
two-thirds overlap with the subjects in the monocytes study,
from the same area (gene expression data: http://www.ebi.ac.
uk/arrayexpress/experiments/E-MTAB-945; genotyping data:
http://www.ebi.ac.uk/ega/EGAD00010000144). We included 413
(unstimulated), 366 (IFN24), 260 (LPS2) and 321 (LPS24) subjects
that have per-sample call rate of >0.92 and autosomal heterozy-
gosity of >0.3225.
Samples of the Cardiogenics monocytes eQTL study (https://
www.ebi.ac.uk/ega/studies/EGAS00001000411) were European
descent and were recruited in ﬁve centres. We restricted analysis
to 396 non-diabetic subjects who had genetic and expression
data of monocytes available in the study. After per-sample call
rate (=1) and autosomal heterozygosity (≥0.335 and ≤0.346) ﬁlter-
ing, 391 remained for further analyses.
Samples from the Fairfax studies were genotyped using the
Illumina HumanOmniExpress-12v1.0 BeadChip. Samples from
the Cardiogenics study were genotyped using Human 610 Quad
Custom arrays. To provide matching dense genotypes in eQTL
samples, we imputed genotypes into 1000 Genomes Phase 1
haplotypes using IMPUTE2 (31) (http://mathgen.stats.ox.ac.uk/
impute/impute_v2.html), for all the disease-associated regions.
Disease-associated regions
Amongst the up-to-date disease-associated regions (http://www.
immunobase.org/downloads/regions-ﬁles-archives/2014-05-04,
archived on 04 May 2014), 545 unique non-MHC autosomal
regions were initially included and 341 regions were used for
colocalisation analysis after multi-stage quality control.
eQTL probeset, SNP and region quality control
For probes including multiple position windows, we used min-
imum andmaximum values of the positions to deﬁne their coor-
dinates. As causal variation may well affect regulatory regions,
we tested for colocalisation for probes in neighbouring genes
within ±200 kb of the disease-associated regions. Although regu-
latory regionsmay lie at a considerable distance from their target
genes, most cis eQTLs are thought to lie within 100 kb of their tar-
get gene (32).We tookapragmatic decision touse a 200-kbwindow
to balance our desire to capture likely cis-mediating disease genes
and the need to limit any multiple testing.
Genotyped SNPs were ﬁltered based on minor allele frequen-
cies MAF (≥0.005), per-SNP call rate (≥0.99) and z-score of Hardy–
Weinberg equilibrium (|z| ≤ 4). The imputed SNPs with poor
quality [MAF < 0.005, |z| > 4 and the imputation output ‘info’
(similar to R2 metrics) <0.3] were also removed. Based on the
table (Annotation Illumina Human-WG-V3-controls_hg18_
V1.0.0_Aug09.txt) provided in ReMOAT (33) (http://remote.
sysbiol.cam.ac.uk/sequence.php), probes with poor quality
scores were excluded. After imputation, we excluded the auto-
somal regions that had no probes within ±200 kb, or <20 common
SNPs with the diseases.
Because the genome assembly of the eQTL data was NCBI36,
whilst that of the Immunochip data as curated in ImmunoBase
and the 1000 Genomes data were GRCh37, we converted the as-
sembly of the SNPs and coordinates of the probes of the eQTL
study to GRCh37 (http://genome.ucsc.edu/cgi-bin/hgLiftOver), be-
fore identifying valid probes and common SNPs with the GWAS.
Probes which indicated colocalising results were checked for
the presence of overlapping SNPs using ReMOAT (http://remoat.
sysbiol.cam.ac.uk/sequence.php). Signals where our peak SNP
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was in LD (r2 > 0.6) with any overlap SNP were excluded, as these
may relate to the effect of the SNP on probe binding, rather than
be a true reﬂection of gene expression.
Colocalisation analyses
Colocalisation analyses were conducted using the R package
coloc, http://cran.r-project.org/web/packages/coloc (4). Themethod
requires summary statistics for each SNP: either P-values and
MAFs, or estimated genotype effects and their standard errors.
As genotypes were available for the eQTL data, we were able to
compute the estimated effects and standard errors (snp.rhs.esti-
mates, package snpStats, http://www.bioconductor.org). For the
ten studied diseases, their P-values and MAFs from 1000 Gen-
omes were used as input. The assumptions of the colocalisation
analyses are as follows:
1. The pair of traits for colocalisation are from independent
studies. Our tests for colocalisation between the expression
of eQTLand the autoimmunediseases satisfy this assumption.
2. Atmost one SNP is causal for either of the traits in each test re-
gion. Under this assumption, we have ﬁve hypotheses: associ-
ationwith neither H0; with either (one of the ten diseases H1 or
monocytes/B cells H2) andwith both (at two independent SNPs
H3, at one shared SNPH4). It is possible thatmore than one SNP
is causal for a trait in a test region. However, in the probable
case that one effect is stronger than another, the method ef-
fectively tests colocalisation of the strongest effect(s) (4).
3. The probability of that a given SNP is causal for a trait is inde-
pendent of the probability that any other given SNP in the re-
gion is causal. This is perhaps counter-intuitive: we might
expect the probability of a given SNP is causal is increased
when another SNP is known to be causal. However, because
we condition on exactly one or zero causal variants, these
higher order probabilities need never be used. This allows
the probability of each hypothesis to be expressed as shown
in Equations (1)–(5) below. Note that this may not apply to as-
sociation relationships, as associations of two or more SNPs
with the trait will not be independent of each other if the
SNPs are in high LD. However, it is plausible for causality.
4. Causal SNPs are either directly genotyped, very well tagged or
well imputed. In the high-density regions of the Immuno-
Chip, imputation of common variants has >95% efﬁciency
(34), justifying this assumption.
Under the above-mentioned assumptions, we set our models as
follows. Supposewe have Q SNPs in a test region. Let p0, p1, p2, p12
denote the prior probabilities of an SNP being causal for neither
trait, disease only, gene expression of the monocytes/B cells
only and both, respectively. These four prior probabilities must
sum up to 1 because they comprise all possible outcomes.
Selection of prior
The prior probabilities corresponding to the ﬁve hypotheses are
as follows:
P0 ¼ PðH0Þ ¼ pQ0 ; ð1Þ
P1 ¼ PðH1Þ ¼ Q × pQ10 p1; ð2Þ
P2 ¼ PðH2Þ ¼ Q × pQ10 p2; ð3Þ
P3 ¼ PðH3Þ ¼ QðQ  1Þ × pQ20 p1 p2; ð4Þ
and
P4 ¼ PðH4Þ ¼ Q × pQ10 p12: ð5Þ
Then, we have that, from Equations (4) and (5), the ratio of P4-
(prior probability of shared causal variant) and P3 (prior probabil-
ity of distinct causal variants):
P4=P3 ¼ PðH4Þ=PðH3Þ ¼ p0 p12ðQ  1Þ p1 p2 : ð6Þ
Both p1 and p2 are set to 1 × 10
−4. In other words, our belief
from previous experience is that 1 in 10 000 SNPs is causal to ei-
ther trait. Obviously, p12 should be smaller than p1 or p2 because it
is less likely for an SNP to be causal for both traits. Consequently,
p0 is approximately equal to 1, and therefore,
P4=P3 ≈
108 p12
ðQ  1Þ : ð7Þ
Hence, for a given region where the number of SNPsQ is ﬁxed,
P4/P3 is proportional to p12 and decreases as the number of SNPs
in a region increases. Likewise, it can be shown that the ratio of
posterior probabilities PP4/PP3 is proportional to p12. Moreover,
both the sums P4 + P3 and PP4 + PP3 increase as p12 increases. To
determine a sensible value for p12, we compared the prior and
posterior relative probabilities for H4|H3 or H4 for three choices
of p12: 10
−7, 10−6 and 10−5 (Fig. 3). Empirically, the optimal choice
of p12 should produce a similar expectation of H4/H3 or H4 under
prior or posterior when the expectation is taken across all pair-
wise analyses. From graphical examination of these results, we
chose p12 = 10
−6 as the most appropriate value, i.e. we expect
that one in 101 SNPs causal for at least one trait is causal for
both traits.
Supplementary Material
Supplementary Material is available at HMG online.
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